ArticleAACE endocrinology and diabetes
Rare Occurrence of Distant Metastases in Prolactinoma: Insights From 2 Cases and Review of the Literature.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aggressive and malignant pituitary tumours: does the sex matter?Pituitary · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Metastatic PitNETs, formerly called pituitary carcinomas, are rare, accounting for approximately 0.2% of pituitary neoplasms, and prolactin-secreting carcinomas with extracranial metastases are even more uncommon. This report describes 2 patients with prolactin-secreting pituitary carcinomas and extracranial metastases. Case Presentation: Case 1: A 42-year-old woman with secondary amenorrhea was diagnosed with a prolactinoma and treated with dopamine agonists and surgery. Despite high-dose cabergoline and radiotherapy, her prolactin remained elevated. Positron emission tomography Imaging revealed a right iliac lesion, and biopsy confirmed metastatic prolactinoma. She responded to combined focal radiotherapy and temozolomide, with normalization of prolactin and symptom relief. Case 2: A 53-year-old man with a prolactinoma underwent multiple surgeries and medical and radiation treatments over 11 years for progressive tumor growth and prolactin elevation. Imaging revealed widespread skeletal and pleuropulmonary metastases. Despite treatment, he died shortly thereafter. Discussion: These cases highlight the malignant potential of aggressive prolactinomas, and the importance of considering metastases in treatment-resistant cases. Histologic features like elevated Ki-67 and p53 expression can aid diagnosis. Radiotherapy combined with temozolomide may control metastases, though response is variable. Conclusion: These cases emphasize the possibility of extracranial metastasis from prolactinomas, and the challenges in managing treatment-resistant cases, underscoring the need for personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.